Nitrogen Attached Indirectly To The Six-membered Hetero Ring By Nonionic Bonding Patents (Class 514/357)
  • Patent number: 10266499
    Abstract: The present invention relates to a compound of formula (I): wherein R1 is R3—IPU and R2 is the acyloxy residue of diclofenac, and specified by the following structures: wherein OH—R3—IPU is selected from and R4 and R5 may be the same or different selected from H and CH3 and salts, solvates and hydrates thereof.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: April 23, 2019
    Inventor: Claus Selch Larsen
  • Patent number: 10253372
    Abstract: The present invention relates to the methods and products for detection of colorectal cancer. Additionally, the present invention relates to methods and products for determining the probability, risk or incidence of colorectal cancer and of colorectal cancer metastasis. The products and methods of the present invention include detecting the level of expression of COL10A1 or MMP11, in combination, from samples, including tissue samples, from humans who currently have been diagnosed with cancer or who were previously diagnosed with cancer and those who are thought to have cancer and are undergoing diagnosis.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: April 9, 2019
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Michael Stürzl, Roland S. Croner, Andreas Konrad
  • Patent number: 10253027
    Abstract: The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.
    Type: Grant
    Filed: July 1, 2014
    Date of Patent: April 9, 2019
    Assignees: Bristol-Myers Squibb Company, Syngene International Limited, Bristol-Myers Squibb Company
    Inventors: Richard A. Hartz, Vijay T. Ahuja, Joanne J. Bronson, Carolyn Diane Dzierba, John E. Macor, Susheel Jethanand Nara, Ramkumar Rajamani
  • Patent number: 10246448
    Abstract: The invention relates to compounds acting as antagonists of Transient Receptor Potential cation channel subfamily M member 8 (TRPM8), and having formula (I): Said compounds are useful in the treatment of diseases associated with activity of TRPM8 such as pain, ischaemia, neurodegeneration, stroke, psychiatric disorders, itch, irritable bowel diseases, cold-induced and/or exacerbated-respiratory disorders, urological disorders, corneal disorders associated to disturbances in the production of the tears and/or altered blinking such as epiphora and dry eye disease.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: April 2, 2019
    Assignee: DOMPÉ FARMACEUTICI S.P.A.
    Inventors: Andrea Aramini, Gianluca Bianchini, Samuele Lillini
  • Patent number: 10238609
    Abstract: Cyanide antidote compositions and methods of use are described herein. A cyanide antidote composition may include a sulfur analog, sulfur analog derivative, or a pharmaceutically acceptable derivative of a sulfur analog.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: March 26, 2019
    Assignee: Sam Houston State University
    Inventors: Ilona Petrikovics, Csaba Jaszberenyi
  • Patent number: 10149860
    Abstract: Compounds, pharmaceutical compositions, and methods of using such compounds and compositions to treat or prevent Alzheimer's disease and related tauopathies through the inhibition of USP-9X and/or enhancement of SCF(?-TrCP).
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: December 11, 2018
    Assignee: Board of Trustees of the Leland Stanford Junior University, Stanford University Office of Technology Licensing
    Inventors: Bingwei Lu, Seongsoo Lee
  • Patent number: 10130907
    Abstract: A class of water lean, organic solvents that can bind with various acid gasses to form acid gas bound molecules having a high degree of intramolecular hydrogen bonding which enables their use as regenerable solvents for acid gas capture. Unlike the other devices described in the prior art, the present invention takes advantage of shortened distances between the portions of the molecule that form hydrogen bonds within the structures when loaded with an acid gas so as to create a molecule with a higher internal bonding affinity and a reduced proclivity for agglomeration with other molecules.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: November 20, 2018
    Assignee: BATTELLE MEMORIAL INSTITUTE
    Inventors: Phillip K. Koech, Deepika Malhotra, David J. Heldebrant, Vassiliki-Alexandra Glezakou, Roger J. Rousseau, David C. Cantu
  • Patent number: 10092656
    Abstract: Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: October 9, 2018
    Assignee: Nektar Therapeutics
    Inventors: C. Simone Jude-Fishburn, Laurie A. VanderVeen, Timothy A. Riley
  • Patent number: 10077245
    Abstract: The present invention provides a compound represented by general formula I or a pharmaceutical acceptable salt thereof, the preparation method therefor and the use thereof in preparing a medicine for treating a neurological disease, such as epilepsy, convulsion, neuropathic pain, acute ischemic stroke, and a neurodegenerative disease. The compound according to present invention has a better absorption in brain tissue when compared with RTG. In addition, the compound provided by present invention has not only a greatly enhanced efficacy, but also a neurotoxicity greatly lower than that of RTG, and thus possesses a wider safety window.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: September 18, 2018
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Min Li, Zhaobing Gao, Yangming Zhang, Haining Hu, Haiyan Xu, Huanan Liu, Xiaoping Pi
  • Patent number: 10064817
    Abstract: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: September 4, 2018
    Assignee: Meda Pharmaceuticals Inc.
    Inventors: Phuong Grace Dang, Brian D. Lawrence, Gul Balwani, Alexander D. D'Addio
  • Patent number: 10059698
    Abstract: A hesperetin aza-cinnamic acid derivative has the following formula (I): R1 is H or alkyl, and R2 and R2 are independently H, alkyl, hydroxy, halogen, nitro, or alkoxy.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: August 28, 2018
    Assignee: Shaanxi University of Science and Technology
    Inventors: Chengyuan Liang, Minyi Jia, Yuecheng Lyu, Xingke Ju, Lei Tian
  • Patent number: 9993464
    Abstract: The invention relates to a pharmaceutical composition comprising methyl (2R.3R)-2-{3-[amino(imino)methyl]benzyl}-3-{[4-(1-oxidopyridin-4-yl)benzoyl]amino}butanoate or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable acidic reacting compound or to an aqueous solution or dispersion of the composition as well as a process for the preparation of the same, methods of using such compositions to treat subjects suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: June 12, 2018
    Assignee: SANOFI
    Inventors: Walter Kamm, Till Bussemer, Doris Andert, Bernd Kuehn, Ernst-Josef Todt
  • Patent number: 9988353
    Abstract: The present invention relates to a novel catalytic hydrogenation of substituted 2-methyl cyanopyridyl derivatives, in particular 3-chloro-5-(trifluoromethyl)pyridin-2-yl]acetonitrile [=Py-CN] to substituted 2-ethylaminopyridine derivatives, in particular 2-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]ethanamine [=Py-ethanamine] or salts thereof in the presence of metal catalysts, in particular palladium catalysts.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: June 5, 2018
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Wahed Ahmed Moradi, Thomas Himmler, Thomas Norbert Mueller, Albert Schnatterer, Guenter Schlegel
  • Patent number: 9937262
    Abstract: The present invention relates to a compound of formula (I): wherein R1 is R3-IPU and R2 is the acyloxy residue of diclofenac or naproxen, and specified by the following structures (A) wherein OH—R3-IPU is selected from (B) and R4 and R5 may be the same or different selected from (C) and salts, solvates and hydrates thereof.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: April 10, 2018
    Inventor: Claus Selch Larsen
  • Patent number: 9914717
    Abstract: The present invention provides compounds of formula (I) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein W, X, n, s, t, and Ra are as described herein. The present invention relates generally to selective inhibitors of histone deacetylase and to methods of making and using them.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 13, 2018
    Assignee: The Broad Institute, Inc.
    Inventors: Edward Holson, Fanny Lazzaro, David Olson, Florence Fevrier Wagner, Michel Weiwer
  • Patent number: 9844560
    Abstract: The present invention provides a method of treating a subject afflicted with lupus nephritis comprising administering to the subject an amount of ginsenoside M1 effective to treat the subject.
    Type: Grant
    Filed: May 4, 2015
    Date of Patent: December 19, 2017
    Inventor: Sheau-Long Lee
  • Patent number: 9839645
    Abstract: The present invention relates to an agent for killing HIV-1-infected cells, comprising a compound represented by formula (I): wherein Ar1 and Ar2 are the same or different and represent a substituted or unsubstituted aromatic group, and X represents —CH2O— or —CH?CH—, its salt, or their solvate, and a combined preparation for simultaneous, separate, or sequential administration in treating or preventing HIV-1 infection, comprising two separate preparations: (a) a preparation comprising a compound represented by the formula (I), its salt, or their solvate, and (b) a preparation comprising an anti-HIV-1 drug.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: December 12, 2017
    Assignee: KAGOSHIMA UNIVERSITY
    Inventor: Mika Okamoto
  • Patent number: 9809557
    Abstract: The present invention relates to novel depot formulations (prodrugs) comprising an immobility promoting unit linked via an ester to an active pharmaceutical ingredient, i.a. common NSAIDs. The novel depot formulations are suitable for intra-articular injections and are soluble at slightly acidic pH to facilitate ease of injection, and sparingly soluble at physiological pH thereby precipitating at the site of administration. The precipitate will slowly dissolve and the active drug is released from dissolved depot formulation following esterase mediated cleavage of the ester link between the immobility promoting unit and the active pharmaceutical agent.
    Type: Grant
    Filed: October 31, 2012
    Date of Patent: November 7, 2017
    Inventor: Claus Selch Larsen
  • Patent number: 9776963
    Abstract: The invention provides for compounds of formula I: wherein Z is absent or (CRARB)nW; each RA and RB is independently (i) H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, haloalkyl, each of which may be optionally substituted; (ii) OH, ORc, NH2, NHRc, NRcRc, SH, S(O)mRc; or (iii) RA and RB together form C(O); W is absent, C(O), C(O)O, C(O)NRcRc, O, S(O)m, or NRcRc; Y is an optionally substituted heterocyclic, optionally substituted heteroaryl, optionally substituted cycloalkyl, optionally substituted aryl, or NRXRY; wherein Rx and Ry are each independently H, alkyl or aryl; X1 is selected from the group consisting of halogen, methyl, and hydroxyl; X2 is a halogen; each Rc is independently alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or heteroaralkyl, each of which may be optionally substituted; m is O, 1, or 2; and n is 1, 2, 3, 4, 5, or 6; and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: October 3, 2017
    Assignees: The Trustees of the University of Pennsylvania, Dana-Farber Cancer Institute, Inc., The Johns Hopkins University, Bryn Mawr College, The Trustees of Columbia University in the City of New York
    Inventors: Joseph G. Sodroski, Navid Madani, Arne Schön, Judith M. LaLonde, Joel R. Courter, Takahiro Soeta, Danny Ng, Ernesto Freire, Amos B. Smith, III, Amy M. Princiotto, Matthew Le-Khac, Wayne A. Hendrickson
  • Patent number: 9763958
    Abstract: The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: September 19, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly, Jie Shen, Marina Bejanian, Rhett Schiffman
  • Patent number: 9725467
    Abstract: Novel fluorinated benzenesulfonamides compounds of general formula (I) can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participate in disease progression.
    Type: Grant
    Filed: October 30, 2012
    Date of Patent: August 8, 2017
    Assignee: VILNIUS UNIVERSITY
    Inventors: Daumantas Matulis, Virginija Dudutiene, Asta Zubriene
  • Patent number: 9708302
    Abstract: The present invention relates to compounds of formula wherein R1 is C4-6-cycloalkyl or C4-6-heterocycloalkyl, which are optionally substituted by one or two substituents, selected from hydroxy or lower alkyl; A is phenyl, pyridinyl or piperidinyl; R2 is hydrogen, halogen, lower alkyl, cyano, C4-6-cycloalkyl, lower alkoxy, lower alkoxy substituted by halogen, or is a five- or six-membered heteroaryl, optionally substituted by lower alkyl; n is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA-ROCHE INC.
    Inventors: Katrin Groebke Zbinden, Emmanuel Pinard, Thomas Ryckmans
  • Patent number: 9624167
    Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl -cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: April 18, 2017
    Assignee: PIMCO 2664 Limited
    Inventors: Lisa Patel, Stephen Allan Smith, Iain Robert Greig, Samuel Cameron Williams
  • Patent number: 9539249
    Abstract: Methods of treatment of multiple sclerosis (MS) with PPAR? agonists, and in particular with the compound of formula (I) known as INT131:
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: January 10, 2017
    Assignee: Intekrin Therapeutics, Inc.
    Inventor: David Weinstein
  • Patent number: 9533963
    Abstract: Alkylamidothiazoles of general formula (I), wherein R 1=—C1-C24 alkyl (linear and branched), —C1-C24 alkenyl (linear and branched), —C1-C8 cycloalkyl, —C1-C8 cycloalkyl-alkylhydroxy, —C1-C24 alkylhydroxy (linear and branched), —C1-C24 alkylamine (linear and branched), —C1-C24 alkylaryl (linear and branched), —C1-C24 alkylaryl-alkyl-hydroxy (linear and branched), —C1-C24 alkyl-heteroaryl (linear and branched), —C1-C24-alkyl-O—C1-C24-alkyl (linear and branched), —C1-C24 alkyl morpholino, —C1-C24 alkyl piperidino, —C1-C24 alkyl piperazino, —C1-C24 alkyl-piperazino-N-alkyl, as well as cosmetic or dermatological preparations having an effective content of one or more alkylamidothiazoles, as well as the use thereof for the cosmetic or dermatological treatment and/or prophylaxis of undesired skin pigmentation.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: January 3, 2017
    Assignee: BEIERSDORF AG
    Inventors: Ludger Kolbe, Cathrin Scherner, Sabrina Breitkreutz, Michael Woehrmann, Tobias Mann, Wolfram Gerwat, Torsten Schlaeger
  • Patent number: 9464042
    Abstract: A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: October 11, 2016
    Assignee: IMMUNOMET THERAPEUTICS INC.
    Inventors: Sung Wuk Kim, Sung Soo Jun, Chang Hee Min, Se Hwan Park, Yong Eun Kim, Duck Kim, Ji Sun Lee, Ju Hoon Oh
  • Patent number: 9452980
    Abstract: The invention relates to compounds of formula wherein R, R1, R2, X, and Y are as defined herein and to a pharmaceutically suitable acid addition salt thereof. Compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds can be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: September 27, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Katrin Groebke Zbinden, Roger Norcross, Philippe Pflieger
  • Patent number: 9428490
    Abstract: The invention generally relates to nuclear transport modulators, e.g CRM1 inhibitors, and more particularly to a compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula (I), or a pharmaceutically acceptable salt or composition thereof, e.g, in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: August 30, 2016
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Vincent P. Sandanayaka, Sharon Shacham, Michael Kauffman, Sharon Shechter, Dilara McCauley, Yosef Landesman, William Senapedis, Jean-Richard Saint-Martin
  • Patent number: 9422276
    Abstract: The present application relates to known and novel aryl- and hetarylcarboxamides of the formula (I) and to their use as medicaments for controlling endoparasites in animals or humans, and also to parasiticidal compositions, in particular endoparasites, comprising aryl- and hetarylcyclylcarboxamides.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: August 23, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Hans-Georg Schwarz, Axel Trautwein, Lothar Willms, Maike Hink, Peter Lümmen, Ulrich Görgens, Pierre-Yves Coqueron, Achim Harder, Claudia Welz, Joerg Nico Greul
  • Patent number: 9346796
    Abstract: Methods and intermediates useful for preparing a compound of formula I: and salts thereof.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: May 24, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Aaron J. Cullen, Richard Hung Chiu Yu
  • Patent number: 9289400
    Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
    Type: Grant
    Filed: August 10, 2011
    Date of Patent: March 22, 2016
    Assignees: Drexel University, Rutgers, The State University of New Jersey
    Inventors: Sandhya Kortagere, Eldo V. Kuzhikandahil
  • Patent number: 9289448
    Abstract: Compounds, pharmaceutical compositions, and methods of using such compounds and compositions to treat or prevent Alzheimer's disease and related tauopathies through the inhibition of USP-9X and/or enhancement of SCF(?-TrCP).
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: March 22, 2016
    Assignee: Board of Trustees of the Leland Stanford Junior University
    Inventors: Bingwei Lu, Seongsoo Lee
  • Patent number: 9232794
    Abstract: The invention relates to the use of succinate dehydrogenase inhibitors, especially of fluopyram, for controlling Sclerotinia ssp., to a method for treating plants or plant parts for controlling Sclerotinia ssp. and to a method for treating seed for controlling Sclerotinia ssp. in the seed and in the plants which grow from the seed, by treating the seed with a succinate dehydrogenase inhibitor.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: January 12, 2016
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ingo Wetcholowsky, Heiko Rieck, Gilbert Labourdette, Jose Augusto Geraldes
  • Patent number: 9198419
    Abstract: The present disclosure is related to the field of agrochemicals, including profungicides of UK-2A and their use to control Black Sigatoka.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: December 1, 2015
    Assignee: Dow AgroSciences LLC
    Inventors: W. John Owen, Leonardo Paniagua, David G. Oimette
  • Patent number: 9179674
    Abstract: The invention relates to compounds of macrocyclic picolinamides of Formula I suitable to control or prevent growth of fungi.
    Type: Grant
    Filed: September 29, 2014
    Date of Patent: November 10, 2015
    Assignee: Dow AgroSciences LLC
    Inventors: Timothy P. Martin, Kevin G. Meyer, Benjamin Nugent, Chenglin Yao, W. John Owen, Anne M. Wilson, Ian O'Callaghan, Jeremy Wilmot, Johnathan E. DeLorbe, William Dent, III
  • Patent number: 9173392
    Abstract: An emulsifiable concentrate (EC) is provided. The EC includes an active component, a solvent component, and an emulsifier component. The active component is present in an amount of from 20 to 90 parts by weight per 100 parts by weight of the emulsifiable concentrate. The solvent component includes 1,2-cyclohexanedicarboxylic acid diisononyl ester. The emulsifier component is present in an amount of from 5 to 15 parts by weight per 100 parts by weight of the emulsifiable concentrate and includes an anionic surfactant, a non-ionic surfactant, and a surfactant including at least one ethylene oxide block. Moreover, the active component is dissolved in the solvent component.
    Type: Grant
    Filed: March 4, 2011
    Date of Patent: November 3, 2015
    Assignee: BASF SE
    Inventors: Michael D. Capracotta, Laura L. Brasher
  • Patent number: 9144239
    Abstract: The invention relates to macrocyclic picolinamides of Formula I and their use as fungicides.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: September 29, 2015
    Assignee: Dow AgroSciences LLC
    Inventors: Kevin G. Meyer, Jr., Karla Bravo-Altamirano, James M. Renga, Jessica Herrick, Benjamin Nugent, Timothy Boebel, Fangzheng Li, Nick X. Wang, W. John Owen, Paul Graupner, Chenglin Yao, Ronald J. Heemstra
  • Patent number: 9090589
    Abstract: Methods for melanoma treatment and prevention with selective nitric oxide synthase inhibitor compounds and related pharmaceutical compositions, alone or in conjunction with one or more other melanoma therapies.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 28, 2015
    Assignees: Northwestern University, The Regents of the University of California
    Inventors: Richard B. Silverman, Frank L. Meyskens, Sun Yang, Haitao Ji, Fengtian Xue, Thomas L. Poulos
  • Patent number: 9078854
    Abstract: The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: July 14, 2015
    Assignee: Allergan, Inc.
    Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly
  • Patent number: 9079834
    Abstract: Compounds of Formula I are disclosed wherein R1, R2, R3A, R3B, R4A, R4B, R5A, R5B, R6A, R6B, R7, R8 and R9 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: July 14, 2015
    Assignee: Merck Canada Inc.
    Inventors: Michael John Boyd, Carmela Molinaro, Amelie Roy, Vouy-Linh Truong
  • Patent number: 9061034
    Abstract: The present invention is directed to preservative-free solutions of bimatoprost and timolol for lowering intra-ocular pressure and treatment of glaucoma.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: June 23, 2015
    Assignee: Allergan, Inc.
    Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly, Jie Shen, Marina Bejanian, Rhett Schiffman
  • Publication number: 20150148360
    Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.
    Type: Application
    Filed: July 19, 2013
    Publication date: May 28, 2015
    Inventors: Jung-Hsin Lin, Jim-Min Fang, Ting-Rong Chen, Jhih-Bin Chen, Ching-Chow Chen, Tzu-Tang Wei
  • Patent number: 9040454
    Abstract: To provide a method which shows excellent effects in controlling pests in a field of soybean, corn or cotton. A method for controlling weeds in a field of soybean, corn or cotton, wherein the field of soybean, corn or cotton is treated with at least one PPO-inhibiting compound selected from the group consisting of flumioxazin, sulfentrazone, saflufenacil, oxyfluorfen, fomesafen-sodium, and the compound of the formula (I): before, at or after seeding with a seed of soybean, corn or cotton treated with one or more insecticidal compounds selected from the group consisting of fipronil, ethiprole, flupyradifurone, sulfoxaflor, beta-cyfluthrin, tefluthrin, and chlorpyrifos.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: May 26, 2015
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Yoshinao Sada
  • Publication number: 20150141472
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).
    Type: Application
    Filed: August 21, 2014
    Publication date: May 21, 2015
    Inventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
  • Publication number: 20150141470
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a MAPK pathway inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and a GEF or HDAC inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a MAPK inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and an effective amount of a GEF or HDAC inhibitor. A method of identifying targets that confers resistance to a MAPK pathway inhibitor is also provided.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 21, 2015
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Publication number: 20150141471
    Abstract: The present invention relates to compounds of the formula (I), wherein the residues R1 to R6, V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds for use in the treatment of diverse disorders, for example cardiovascular disorders like thromboembolic diseases or restenoses. The compounds of the invention are effective antagonists of the platelet LPA receptor LPAR5 (GPR92) and can in general be applied in conditions in which an undesired activation of the platelet LPA receptor LPAR5, the mast cell LPA receptor LPAR5 or the microglia cell LPA receptor LPAR5 is present, or for the cure or prevention of which an inhibition of the platelet, mast cell or microglia cell LPA receptor LPAR5 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in medicaments, and pharmaceutical compositions comprising them.
    Type: Application
    Filed: May 16, 2013
    Publication date: May 21, 2015
    Inventors: Marc Nazare, Detlef Kozian, Andreas Evers, Werngard Czechtizky
  • Patent number: 9035065
    Abstract: The present invention is directed to ethanamine compounds, pharmaceutical compositions comprising the same, and methods of treating depression by administering the ethanamine compound.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: May 19, 2015
    Assignee: AstraZeneca AB
    Inventors: Michael Balestra, Peter Bernstein, Glen E. Ernst, William Frietze, John McCauley, David Nugiel, Lihong Shen
  • Publication number: 20150133510
    Abstract: The present invention relates to tertiary amines of formula (I) for use in therapy, particularly for use in treating cardiovascular disorders. The compounds have been found to regulate phospholamban phosphorylation by interfering with the A-kinase anchor protein 18delta (AKAP185) binding to the PKA substrate phospholamban. The compounds share a tri(alkylaryl/alkylheteroaryl)amine structure.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 14, 2015
    Applicant: Universitetet I Oslo
    Inventors: Kjetil Tasken, Birgitte Lygren, Ellen Ostensen, Jo Klaveness
  • Publication number: 20150133509
    Abstract: The present invention provides a tree trunk injection agent whereby pathogenic fungi and/or pests in trees can be effectively controlled merely by a short-time application in a low chemical dose, and a method for controlling tree diseases using the tree trunk injection agent. According to one embodiment of the present invention, the tree trunk injection agent is obtained by adding, to an aqueous solution of an insecticidal component such as acetamiprid, a hardly soluble fungicidal component such as thiophanate-methyl so as to suspend the hardly soluble fungicidal component, wherein a particle size based on 50% volume of the fungicidal component is 4 ?m or less, or adding thereto at least one fungicidal component selected from a group consisting of triflumizole and metconazole.
    Type: Application
    Filed: April 30, 2013
    Publication date: May 14, 2015
    Applicant: NIPPON SODA CO., LTD.
    Inventors: Takahiro Maekawa, Yasuhiro Omori
  • Patent number: 9023874
    Abstract: The invention relates to alkylsulfide derivatives compounds of formula I as hereunder depicted or the enantiomers or veterinarily acceptable salts thereof which are useful for combating or controlling invertebrate pests, in particular arthropod pests and nematodes. The invention also relates to methods for controlling invertebrate pests by using these compounds and to plant propagation material and to agricultural and veterinary compositions comprising said compounds. wherein U, R1, R2, R3U, X, n and p are defined as in the description.
    Type: Grant
    Filed: November 11, 2010
    Date of Patent: May 5, 2015
    Assignee: Merial, Inc.
    Inventors: Sebastian Soergel, Ralph Paulini, Steffen Gross, Carsten Beyer, Matthias Pohlman, Henricus Maria Martinus Bastiaans, Michael Rack, Deborah L. Culbertson, Douglas D. Anspaugh, Sarah Thompson, Vincent Salgado